Clinical Scorecard: Analysis of the Tumor Microenvironment in Locally Advanced Gastric Cancer and Discovery of Spatial Predictive Biomarkers Linked to Effective Neoadjuvant Immunochemotherapy

At a Glance

Key Highlights

• Neoadjuvant immunochemotherapy (nICT) shows variable clinical responses in LAGC.
• NOTUM, SERPINA3, and CD8+ T cell density are identified as predictive biomarkers for nICT response.
• Digital spatial profiling (DSP) and multiplex immunofluorescence (mIF) were utilized for TME analysis.
• A six-gene signature correlates with survival and immune infiltration in gastric cancer.
• Tislelizumab combined with SOX chemotherapy demonstrated significant overall survival benefits.

Guideline-Based Recommendations

Diagnosis

• Utilize TNM classifications for staging LAGC.
• Consider endoscopic biopsies for TME profiling.

Management

• Implement neoadjuvant immunochemotherapy with PD-1 inhibitors like tislelizumab.
• Combine immunotherapy with chemotherapy for improved outcomes.

Monitoring & Follow-up

• Assess tumor response through pathological evaluation post-treatment.
• Monitor immune cell infiltration and biomarker expression in TME.

Risks

• Variable treatment responses with some patients experiencing minimal clinical benefit.
• Potential adverse effects associated with immunotherapy.

Patient & Prescribing Data

Patients diagnosed with locally advanced gastric cancer (LAGC) receiving neoadjuvant therapy.

Tislelizumab combined with SOX regimen shows a major pathological response rate of 61.9%.

Clinical Best Practices

• Conduct comprehensive TME profiling to identify predictive biomarkers.
• Utilize spatial analysis techniques to enhance precision in immunotherapy.

Related Resources & Content

• Study on Neoadjuvant Immunochemotherapy in Gastric Cancer